0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Drug Therapy
 201-220 of 588 Articles
Viewpoint | 
Deborah Dowell, MD, MPH; Hillary V. Kunins, MD, MPH, MS; Thomas A. Farley, MD, MPH
JAMA. 2013;309(21):2219-2220. doi:10.1001/jama.2013.5794.

Original Contribution |  FREE
Jörg D. Leuppi, MD, PhD; Philipp Schuetz, MD; Roland Bingisser, MD; et al.
JAMA. 2013;309(21):2223-2231. doi:10.1001/jama.2013.5023.
Includes: Supplemental Content

Editorial | 
Don D. Sin, MD; Hye Yun Park, MD, PhD
JAMA. 2013;309(21):2272-2273. doi:10.1001/jama.2013.5644.

Viewpoint | 
Bruce M. Psaty, MD, PhD; Steven N. Goodman, MD, MHS, PhD; Alasdair Breckenridge, MD
JAMA. 2013;309(20):2103-2104. doi:10.1001/jama.2013.4503.

Viewpoint | 
Zachary A. Marcum, PharmD, MS; Mary Ann Sevick, ScD, RN; Steven M. Handler, MD, PhD
JAMA. 2013;309(20):2105-2106. doi:10.1001/jama.2013.4638.

News From the Centers for Disease Control and Prevention | 
JAMA. 2013;309(19):1986. doi:10.1001/jama.2013.4949.

Viewpoint | 
Rena M. Conti, PhD; Peter B. Bach, MD, MAPP
JAMA. 2013;309(19):1995-1996. doi:10.1001/jama.2013.4156.

Medical News and Perspectives | 
Bridget M. Kuehn, MSJ
JAMA. 2013;309(18):1883-1884. doi:10.1001/jama.2013.4015.

Original Contribution |  FREE
Elizabeth D. Lowenthal, MD, MSCE; Jonas H. Ellenberg, PhD; Edwin Machine, MPH; et al.
JAMA. 2013;309(17):1803-1809. doi:10.1001/jama.2013.3710.
Includes: Supplemental Content

Original Contribution |  FREE
Sina Gallo, RD, MSc; Kathryn Comeau, RD, MSc; Catherine Vanstone, RN, MSc; et al.
JAMA. 2013;309(17):1785-1792. doi:10.1001/jama.2013.3404.
Includes: CME, Supplemental Content

Viewpoint | 
Lawrence O. Gostin, JD; Gillian J. Buckley, MPH, PhD; Patrick W. Kelley, MD, DrPH
JAMA. 2013;309(16):1693-1694. doi:10.1001/jama.2013.3048.

Editorial | 
Kimford J. Meador, MD; David W. Loring, PhD
JAMA. 2013;309(16):1730-1731. doi:10.1001/jama.2013.4001.

Health Agencies Update | 
Bridget M. Kuehn, MSJ
JAMA. 2013;309(16):1674. doi:10.1001/jama.2013.4243.

Medical News and Perspectives | 
Bridget M. Kuehn, MSJ
JAMA. 2013;309(16):1669-1670. doi:10.1001/jama.2013.3616.

Original Contribution |  FREE
Jakob Christensen, PhD; Therese Koops Grønborg, MSc; Merete Juul Sørensen, PhD; et al.
JAMA. 2013;309(16):1696-1703. doi:10.1001/jama.2013.2270.
Includes: Supplemental Content

Viewpoint | 
Richard Smith, MB, ChB, MSc, FRCPE; Tara McCready, MBA, PhD; Salim Yusuf, DPhil, FRCPC, FRSC
JAMA. 2013;309(15):1595-1596. doi:10.1001/jama.2013.3180.

Viewpoint | 
Javed Butler, MD, MPH; Gregg C. Fonarow, MD; Mihai Gheorghiade, MD
JAMA. 2013;309(15):1593-1594. doi:10.1001/jama.2013.1063.

Medical News and Perspectives | 
Bridget M. Kuehn, MSJ
JAMA. 2013;309(15):1573-1574. doi:10.1001/jama.2013.2922.

Capitol Health Call | 
Mike Mitka, MSJ
JAMA. 2013;309(14):1452. doi:10.1001/jama.2013.2985.

Capitol Health Call | 
Mike Mitka, MSJ
JAMA. 2013;309(14):1452. doi:10.1001/jama.2013.3563.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal
From The JAMA Network
JAMA Internal Medicine
Invited Commentary  | 
Finding Meaningful Patterns in Adverse Drug Event Reports
Joshua J. Gagne, PharmD, ScD
JAMA Internal Medicine
Invited Commentary  | 
Dopamine Receptor Agonist Drugs and Impulse Control Disorders
Howard D. Weiss, MD; Gregory M. Pontone, MD
JAMA Internal Medicine
Original Investigation  | 
Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
Thomas J. Moore, AB; Joseph Glenmullen, MD; Donald R. Mattison, MD, MS
JAMA Dermatology
Case Report/Case Series  | 
Drug-Associated Dermatomyositis Following Ipilimumab Therapy:  A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade
Shirwa Sheik Ali, BSc; Allison L. Goddard, MD; Jason J. Luke, MD; et al.